{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04383210\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"CRESTONE","nct_id":"NCT04383210","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=crestone-nct04383210. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"A minimum of 55 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, excluding prior ERBB-directed therapy.\n\nSeribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions, who have received prior standard treatment, including prior ERBB-directed therapy.\n\nSeribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"Up to 10 adult advanced solid tumor patients harboring NRG1 gene fusions lacking an EGF-like domain, who have received prior standard treatment, which may have included prior ERBB-directed therapy.\n\nSeribantumab 1-h IV infusion at various doses once weekly, every 2 weeks and every 3 weeks, during the induction, consolidation and maintenance dosing phases, respectively.","label":"Cohort 3","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-02-28","type":"ACTUAL"},"conditions":["Locally Advanced Solid Tumor","Metastatic Solid Tumor","Pancreatic Cancer","Lung Cancer","Head and Neck Cancer","Breast Cancer","Kidney Cancer","Colorectal Cancer","Bladder Cancer","Ovarian Cancer","Sarcoma","Gallbladder Cancer","Bile Duct Cancer","Esophageal Cancer","Uterine Cancer","Cholangiocarcinoma","Prostate Cancer"],"enrollment":{"count":54,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Seribantumab","otherNames":[],"type":"DRUG"}],"last_update":"2025-04-03","lead_sponsor":"Elevation Oncology","official_title":"CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients With Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2024-02-28","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate","timeFrame":"Up to 12 months"}],"references":[{"citation":"Patil T, Lin JJ, Cheema PK, Carrizosa DR, Burkard ME, Elamin YY, Desai J, Patel JD, Nagasaka M, Reckamp KL, Waqar SN, Bauman JR, Schram AM, Gadgeel SM, Ma PC, Konduri K, Nguyen D, Misleh J, Bleeker J, Weiss M, Thavaneswaran S, Haura EB, Deegan M, Kaufman J, Srivastava J, Jansen VM, Liu SV. CRESTONE: A Phase II Study of the Efficacy and Safety of the HER3 Monoclonal Antibody, Seribantumab, in Solid Tumors With Neuregulin-1 (NRG1) Fusions. JCO Precis Oncol. 2025 Aug;9:e2500221. doi: 10.1200/PO-25-00221. Epub 2025 Dec 22.","pmid":"41428976","type":"DERIVED"}],"start_date":{"date":"2020-09-29","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","url":"https://clinicaltrials.gov/study/NCT04383210"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/crestone-nct04383210"}